

## Diagnostic of a hepatic syndrome and its treatment

### Domaines d'application

Hepatic syndrome -Cholesterol lithiasis

### Contexte

Cholesterol lithiasis is the most common form of cholelithiasis (80%). Its prevalence is estimated, taking all ages into account, to be 10 to 20% of the population in industrialized countries.

The MDR3 gene's product is a phospholipid translocator. It is expressed in hepatocytes and provides phosphatidylcholine translocation, thus leading to secretion of this phospholipid into the bile.

Mutations of the MDR3 gene are associated with cholesterol biliary microlithiasis and intrahepatic cholestasis in hepatic syndrome occurring in the young adult.

### Description de la Technologie

We propose a cost-and time-efficient test to detect MDR3 mutations from a nucleic acid sample extracted from peripheral blood mononuclear cells for the diagnostic of cholelithiasis, and a treatment using pharmaceutical composition comprising ursodeoxycholic acid.

AP-HP is currently seeking companies or entrepreneurs to license this minimally invasive test and its treatment.

### Stade de Développement

Clinical data available

### Propriété Intellectuelle

EP, US, CA Patents